References
1. World Health Organization. Global Hepatitis Report; 2017. Disponible en: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
2. Thein H-H, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008;48(2):418-31.
3. Ministerio de inclusión, seguridad social y migraciones. Portal de inmigración. Disponible en: http://extranjeros.mitramiss.gob.es/es/estadisticas/operaciones/con-certificado/index.html
4. Alarcón-Linares ME, Torres-Cantero A, Subirá C, et al. Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropiate? Rev Esp Enf Dig 2019;111(8):615-25. DOI: 10.17235/reed.2019.6117/2018
5. Estirado Gómez A, Soledad M, Gil J, et al. Elaboración del informe: Coordinación del 2o Estudio de Seroprevalencia en España; 2017.
6. Daw MA, El-Bouzedi A, Ahmed MO, et al. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Med Infect Dis 2016;14(5):517-26.
7. Lazarus JV, Bromberg DJ, Del Amo J, et al. Hepatitis C prevalence among the migrant population in Spain: a systematic review and meta-analysis. Enferm Infecc Microbiol Clin 2019;37(4):222-30.
8. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027
9. Tierney AR, Huepfel W, Shaukat AP, et al. Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. J Immigr Minor Heal 2019;21(3):549-54.
10. Welzel TM, Hinrichsen H, Sarrazin C, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. Viral Hepat 2017;24(10):840-9.
11. Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis Lampertico P, et. al. Journal of Hepatology 2020;72:1112-21.
12. Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/Velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver International 2020;40:1841-52.
13. Cabezas F, Gea F, Llerena S, el al. Efectividad y seguridad del tratamiento con Sofosbuvir/ledipasvir, con/sin ribavirina en pacientes monoinfectados con hepatitis crónica por VHC en la práctica clínica real. Gastroenterol Hepatol 2016,39(Supl. 1):11-2.
14. Cooper CL, Thavorn K, Damian E, et al. Hepatitis C virus infection outcomes among inmigrants to Canada: a retrospective cohort analysis. Annals of Hepatology 2017;16:720-6.
15. Greenaway C, Azoulay L, Allard R, et al. A population-based study of crhonic hepatitis C in inmigrants and noninmigrants in Quebec, Canada. BMC infectious disease 2017;17:140. DOI: 10.1186/s12879-017-2242-y
16. Greenaway C, Makarenko I, Chakra CNA, et al. The effectiveness and cost-effectiveness of hepatitis C screening for migrants in the EU/EEA: A systematic review. Int J Environ Res Public Health 2018;15(9):2013. DOI: 10.3390/ijerph15092013
17. Childs K, Davis C, Montague S, et al. Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: Implications for global elimination. Journal of Hepatology 2019;70(1):e111-2. DOI: 10.1016/S0618-8278(19)30199-9
18. Coppola N, Alessio L, Onorato L, et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infectious Diseases of Powerty 2019;8:17.